Form 4: Eli Lilly Director Defers Compensation into Stock Units

Eli Lilly & Co. Director Ralph Alvarez acquired 15.705 shares of common stock, deferring cash compensation into stock units under a company plan.

Summary

• Director Ralph Alvarez acquired 15.705 shares of Eli Lilly & Co. common stock.
• The transaction occurred on September 15, 2025, at a price of $748.19 per share.
• These shares were acquired by deferring cash compensation into stock units under the Lilly Directors' Deferral Plan.
• The stock units will be settled in common stock shares upon Mr. Alvarez's separation from service.
• Following this transaction, Mr. Alvarez directly beneficially owns 55,137.85 shares and indirectly owns 758 shares through a Trust.

Sentiment

Score: 7

Explanation: The filing indicates a director's continued investment in the company through deferred compensation, which is generally a positive signal of alignment with shareholder interests and confidence in the company's long-term prospects. It's a routine, expected transaction, not a major catalyst.

Positives

• Director Ralph Alvarez is increasing his beneficial ownership in Eli Lilly & Co. through deferred compensation, aligning his interests with shareholders.
• The deferral plan indicates a structured approach to executive compensation and long-term commitment.

Future Outlook

The acquired shares, deferred as stock units, will be settled in common stock following the reporting person's separation from service, indicating a future payout event tied to his tenure.

Management Comments

• At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

This is a routine insider transaction for director compensation. It reflects standard corporate governance practices where directors often elect to receive equity-based compensation to align their interests with long-term shareholder value, common across the pharmaceutical and broader corporate sectors.

Comparison to Industry Standards

• The practice of directors deferring cash compensation into stock units is a common corporate governance mechanism, aligning director incentives with long-term company performance, similar to practices at peer pharmaceutical companies like Pfizer or Merck.
• The specific value of shares acquired and total beneficial ownership would need to be compared against other Eli Lilly directors or directors at comparable large-cap pharmaceutical companies to assess if it's within typical ranges for director equity holdings.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive signal of director confidence and alignment of interests.
• Management/Employees: Reflects standard compensation practices for directors.

Next Steps

• Settlement of the stock units into common stock shares upon Ralph Alvarez's separation from service.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a director defers cash compensation into company stock units. While it signals confidence and aligns director interests with shareholders, it is a standard compensation event and does not provide new material information to warrant a change in investment recommendation. The transaction itself is not a significant catalyst for stock price movement.

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Director Compensation, Stock Units, Deferred Compensation, Ralph Alvarez, Beneficial Ownership